These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 6372924)

  • 21. Sublingual apomorphine: new preparation. In erectile disorders: a narrow therapeutic margin.
    Prescrire Int; 2002 Jun; 11(59):76-9. PubMed ID: 12068841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy.
    Ettigi P; Nair NP; Lal S; Cervantes P; Guyda H
    J Neurol Neurosurg Psychiatry; 1976 Sep; 39(9):870-6. PubMed ID: 993808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth hormone responses to graded doses of apomorphine HCl in schizophrenia.
    Cleghorn JM; Brown GM; Brown PJ; Kaplan RD; Mitton J
    Biol Psychiatry; 1983 Aug; 18(8):875-85. PubMed ID: 6137249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of a dopamine agonist (apomorphine) on experimental and spontaneous pain in patients with chronic radicular pain: A randomized, double-blind, placebo-controlled, cross-over study.
    Haddad M; Pud D; Treister R; Suzan E; Eisenberg E
    PLoS One; 2018; 13(4):e0195287. PubMed ID: 29621293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The acute effect of haloperidol and apomorphine on the severity of stuttering.
    Burns D; Brady JP; Kuruvilla K
    Biol Psychiatry; 1978 Apr; 13(2):255-64. PubMed ID: 667231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pragmatic use of apomorphine at the end of life.
    Dewhurst F; Lee M; Wood B
    Palliat Med; 2009 Dec; 23(8):777-9. PubMed ID: 19837701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apomorphine's antipsychotic activity.
    Schaffer MH; Davis JM; Tamminga CA
    Arch Gen Psychiatry; 1985 Sep; 42(9):927-8. PubMed ID: 2864035
    [No Abstract]   [Full Text] [Related]  

  • 28. Apomorphine and schizophrenia.
    Johns CA; Levy MI; Davis BM; Mohs RC; Kendler KS; Mathe AA; Trigos G; Horvath TB; Davis KL
    Psychopharmacol Bull; 1984; 20(1):103-7. PubMed ID: 6718635
    [No Abstract]   [Full Text] [Related]  

  • 29. The effect of apomorphine on blink kinematics in subhuman primates with and without facial nerve palsy.
    Baker RS; Radmanesh SM; Abell KM
    Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2933-8. PubMed ID: 12202512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apomorphine: North American clinical experience.
    Stacy M
    Neurology; 2004 Mar; 62(6 Suppl 4):S18-21. PubMed ID: 15037667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Catecholaminergic drugs in chronic schizophrenia.
    Brambilla F; Scarone S; Ponzano M; Maffei C; Nobile P; Rovere C; Guastalla A
    Neuropsychobiology; 1979; 5(4):185-200. PubMed ID: 375121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bell's palsy-induced blepharospasm relieved by passive eyelid closure and responsive to apomorphine.
    Cattaneo L; Chierici E; Pavesi G
    Clin Neurophysiol; 2005 Oct; 116(10):2348-53. PubMed ID: 16098807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of apomorphine on regional cerebral blood flow in schizophrenia.
    Daniel DG; Berman KF; Weinberger DR
    J Neuropsychiatry Clin Neurosci; 1989; 1(4):377-84. PubMed ID: 2521086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of clozapine on apomorphine-induced growth hormone secretion and serum prolactin concentrations in schizophrenia.
    Nair NP; Lal S; Cervantes P; Yassa R; Guyda H
    Neuropsychobiology; 1979; 5(3):136-42. PubMed ID: 431802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Various aspects of the interaction between the dopamine and opiate systems in schizophrenia].
    Anokhina IP
    Vestn Akad Med Nauk SSSR; 1982; (1):37-40. PubMed ID: 7064531
    [No Abstract]   [Full Text] [Related]  

  • 36. Therapy of migraine by modulating dopamine hypersensitivity: its effect on mood and pain.
    Lai M; Loi V; Pisano MR; Del Zompo M
    Int J Clin Pharmacol Res; 1997; 17(2-3):101-3. PubMed ID: 9403364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopamine agonists in the treatment of schizophrenia.
    Del Zompo M; Bocchetta A; Piccardi MP; Corsini GU
    Prog Brain Res; 1986; 65():41-8. PubMed ID: 3786793
    [No Abstract]   [Full Text] [Related]  

  • 38. Blockade by apomorphine of haloperidol-induced dyskinesia in schizophrenic patients.
    Gessa R; Tagliamonte A; Gessa GL
    Lancet; 1972 Nov; 2(7784):981-2. PubMed ID: 4116875
    [No Abstract]   [Full Text] [Related]  

  • 39. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection.
    Hauser RA; Isaacson S; Clinch T;
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1171-6. PubMed ID: 25239603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing 'off' periods in patients with established Parkinson's disease.
    Grosset KA; Malek N; Morgan F; Grosset DG
    Eur J Neurol; 2013 Nov; 20(11):1445-50. PubMed ID: 23350812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.